As of 2025-12-14, the Fair Value of Citius Pharmaceuticals Inc (CTXR) is -9.82 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.12 USD, the upside of Citius Pharmaceuticals Inc is -976.44%.
With the market price of 1.12 USD and our fair value calculation, Citius Pharmaceuticals Inc (CTXR) is not a good investment. Investing in CTXR stocks now will result in a potential loss of 976.44%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 5Y Avg | |
| Net income | -17.55 | -23.05 | -33.64 | -32.54 | -39.14 | -29.18 |
| YoY growth | -12.79% | -31.34% | -45.94% | 3.26% | -20.27% | -21.42% |
| Market Cap (mil) | 23.09 |
| P/E | |
| Forward P/E |
| EPS | -1.96 |
| Avg earnings growth rate | -21.42% |
| TTM earnings | -40.47 |